deltatrials
Completed PHASE3 NCT00865501

Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease

Sponsor: University of Erlangen-Nürnberg Medical School

Conditions Primary Hypertension
Interventions placebo spironolactone
Updated 5 times since 2017 Last updated: Jul 6, 2012 Started: Mar 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

A PHASE3 clinical study on Primary Hypertension, this trial is completed. The trial is conducted by University of Erlangen-Nürnberg Medical School and has accumulated 5 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Erlangen-Nürnberg Medical School
Data source: University of Erlangen-Nürnberg Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Erlangen, Germany